SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense investor focus on geopolitical escalation in the Middle East, particularly concerns over supply chain disruptions at the Strait of Hormuz and the Red Sea. Community discussions are centered on potential oil price surges, the impact of possible ground operations, and the ongoing volatility across equity markets as energy sector exposure dominates trading sentiment.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is seeing heightened market interest and momentum following a fresh equity infusion from institutional backers, which has helped stabilize liquidity and fuel optimism for upcoming model deliveries. Community members are actively debating the stock's potential for a turnaround while closely monitoring retail registration data and long-term production strategies.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting positive long-term Phase 3 results for its lead drug, sonelokimab, which investors are calling a potential 'best-in-class' treatment for hidradenitis suppurativa. The community is actively discussing the drug's deepening efficacy and safety profile while speculating that the updated clinical data will reignite interest from potential pharmaceutical acquirers.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrock on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is trending following its market debut as a pure-play photonic quantum computing company, drawing intense attention from retail investors debating its long-term potential in AI and AGI. Discussions are dominated by community frustration over perceived trading platform restrictions and alleged market manipulation, alongside intense analysis of its initial float and valuation compared to sector peers.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is currently trending as the market weighs significant institutional buying from firms like ARKQ against persistent short interest and frustration over a lack of direct executive communication regarding 2026 growth milestones. Investors remain fixated on the disconnect between the company's aggressive international expansion into the Middle East and Asia and the stock's sluggish price performance relative to its robotaxi peers.

Invesco CurrencyShares Euro Trust - Units of fractional undivided beneficial interest

Invesco CurrencyShares Euro Trust

Invesco CurrencyShares Euro Trust is actively monitored as traders weigh conflicting signals from the European Central Bank and the Federal Reserve against a backdrop of global economic uncertainty. Market participants are focused on key macro catalysts, including energy-related inflation fears and shifting rate-cut expectations, which have heightened volatility in EUR/USD and prompted technical analysis on potential breakout trends.

Invesco CurrencyShares Japanese Yen Trust - Units of fractional undivided beneficial interest

Invesco CurrencyShares Japanese Yen Trust

The Invesco CurrencyShares Japanese Yen Trust is currently a focal point for traders monitoring the global carry trade, with many market participants warning that a strengthening yen could trigger significant volatility across equities and risk assets. The community is closely debating the potential for a larger unwind of yen-funded positions and questioning the currency's historical role as a reliable safe haven amidst shifting macro instability.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is experiencing significant volatility following a critical short-seller report alleging improper revenue recognition and channel stuffing practices. While the company has officially refuted these claims and highlighted its robust growth and buyback program, the community remains divided between investors viewing the sell-off as an extreme buying opportunity and those concerned about the lack of a more comprehensive, point-by-point rebuttal from management.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The SPDR Dow Jones Industrial Average ETF (DIA) is currently at the center of investor anxiety as market participants debate the authenticity of potential ceasefire negotiations between the U.S. and Iran. While optimistic headlines regarding energy infrastructure pauses have provided short-term relief, the community remains deeply divided, with many actively discussing the risk of escalation, rising oil prices, and the broader economic stability of the market under existing geopolitical tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is facing intense volatility as market sentiment reacts to aggressive military posturing in the Middle East and concerns over potential ground operations, leading to widespread investor uncertainty. Investors are actively debating the intersection of geopolitical instability with the stock's long-term viability, while conflicting reports regarding ceasefire progress continue to fuel heated discussions about the influence of political rhetoric on asset values.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S.&nbsp;</li><li>With this step, ART100 moves from regulatory clearance to active commercial availability, the company said.</li><li>Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business</li></ul>Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.<a href="https://stocktwits.com/symbol/IINN">IINN shares</a> gave up premarket gains and fell around 3% after the opening bell.&nbsp;The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.<h2 class="st-heading-2">ART100 Regulatory Clearance</h2>With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.“By securing this approval, we are laying the foundation for potentially long-term, high-quality revenue. This validation from a world-class, data-driven health ecosystem serves as a powerful reference case as we accelerate our commercialization efforts in the U.S. and other global markets,” said Dagi Ben-Noon, CEO of Inspira Technologies.The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.<h2 class="st-heading-2">Top U.S. Medical Center Clears ART100&nbsp;</h2>In January, Inspira Technologies’ ART100 system completed clinical evaluation at a top U.S. academic medical centre and moved into the budgeted procurement stage. The system successfully treated about 30 patients across surgeries, transplants, and other critical procedures, leading to its adoption into routine clinical workflows.&nbsp;With the evaluation phase now closed, the hospital has begun an internal process to purchase multiple ART100 units, pending final budget approval.Earlier, Inspira announced a non-binding term sheet for a proposed two-part deal to acquire an advanced liquid biopsy diagnostics business. The transaction also includes a planned $15 million strategic equity investment.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.The stock has shed around 25% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did IINN Stock Surge 28% In Pre-Market Today?

The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.

Equity

All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy

Inspira Technologies OXY (IINN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Inspira Technologies OXY B.H.N. (IINN) on Friday announced that it has received U.S. Patent approval for the core technology of its ART500 device.The firm stated that the device is key to penetrating the $20 billion estimated market for advanced respiratory support. The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500’s functionality, design, and clinical applications.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IINN">IINN stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_2_07_05_PM_png_792c0ec45d.webp" alt="IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="577" height="61"><figcaption>IINN's Sentiment Meter and Message Volume as of 2:07 p.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they are loading up on the shares of the company.<stembedurl>https://stocktwits.com/VSWeWork/message/626246424</stembedurl>Another, however, sounded disappointed at the stock’s performance.<stembedurl>https://stocktwits.com/Kyavic77/message/626229410</stembedurl>The ART500 system is designed to provide extracorporeal oxygenation at low flow rates while maintaining patient safety and treatment efficiency. According to the firm, this targets a patient population that requires respiratory support but may not be sick enough for traditional, high-flow ECMO systems.Inspira CEO Dagi Ben-Noon <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/22/3137823/0/en/Inspira-Receives-U-S-Patent-Approval-for-the-ART500-Core-Technology-Key-Patent-Positions-the-Company-to-Dominate-20-Billion-Estimated-Market.html">said</a> that the patent has profound business implications for the company. “While our ART100 system is already generating commercial momentum, this move fortifies our future and gives us the clear runway…,” he said.Earlier this month, Inspira <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/19/3135699/0/en/Inspira-Secures-27-Million-Government-Binding-Purchase-Order-for-ART100-Systems-with-Full-Payment-in-2025.html">said</a> that a national ministry of health in Africa has placed a $27 million binding purchase order for its ART100 systems. The purchase order provides for full contractual payment scheduled for completion during 2025.IINN stock is up by 17% this year and by about 9% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-believes-these-are-five-things-that-could-initiate-tesla-rally/chsZeukRdKP">Gary Black Believes These Are The Five Things That Could Initiate A Tesla Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Inspira Technologies Receives US Patent Clearance For Core Technology Of Its ART500 Device: Retail Loads Up On The Stock 

The newly received patent provides protection at least until the year 2043, covering key claims related to the ART500 device’s functionality, design, and clinical applications.

Inspira Technologies Oxy B.H.N. Ltd. is a specialty medical device company, which engages in research, development, manufacturing, and marketing of proprietary life support technology with a vision to supersede traditional mechanical ventilators, or Mechanical Ventilation, which is the standard of care today for the treatment of acute respiratory failure. The company was founded by Dagi Shahar Ben Noon, Joe Hayon, and Udi Nussinovitch in July 2017 and is headquartered in Raanana, Israel.

Inspira Technologies Oxy B.H.N. Ltd

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

IINN
Inspira Technologies Oxy B.H.N. Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IINN News

IINNInspira Technologies Oxy B.H.N. Ltd